Harry Rubash

Inivata has appointed Peter Collins as the firm's chief business officer. Prior to Inivata, Collins most recently held senior leadership positions at Guardant Health. He has also served as chief business officer at Yourgene Health. Prior to Yourgene, Collins served as VP, head of diagnostics at GSK, as well as VP of pharma business development at Qiagen. He was also the founder and board member of Epemed. 

Edward Strong has been named scientific director of iAssay, a firm developing an open platform that consolidates utilization of a range of point-of-care tests with a single cloud-connected, handheld reader. Strong, a geneticist, formerly cofounded and served as CEO of MedGenomics, and also served as interim CEO of LifeGenomix.

Magnolia Medical Technologies has appointed two former Becton Dickinson senior executives to its medical and scientific advisory board. They are Richard Ivey, retired worldwide vice president of research and development for Becton Dickinson's life sciences diagnostic systems business, and Paul Goldenbaum, retired director of research and development for BD's diagnostic instrument systems division.

With BD, Ivey led an R&D team of several hundred engineers and scientists focused on diagnostic technologies, including infectious disease diagnostic instrumentation, laboratory automation engineering, microbiology, molecular biology, immunochemistry, and cytology.

With BD, Goldenbaum was charged with improving and expanding the Bactec blood culture media product line for sepsis testing. In this role, he developed the blood culture media for all generations of the Bactec blood culture system including radiometric, resin media, non-radiometric, and the current fluorescent, non-invasive media.

Fran Soistman has joined the scientific board of Alveo Technologies. He has more than 40 years of experience in the healthcare and managed care sector, including as executive vice president for Aetna. As a member of Alveo's scientific advisory board, Soistman will help guide the firm's efforts to implement its infectious disease testing technologies. Alameda, California-based Alveo is developing its be.well platform, a point-of-care, at-home diagnostic tool.

Veracyte has promoted Richard Kloos to executive medical director, overseeing the company's global medical affairs in all clinical areas addressed by its genomic tests. Kloos previously served as senior medical director of endocrinology at Veracyte, which he joined in 2012. He was previously a professor of endocrinology and metabolism, and nuclear medicine at Ohio State University, and was attending physician at the OSU Comprehensive Care Center. He was also codirector of the OSU Thyroid Cancer Unit and served a four-year term as secretary and chief operating officer for the American Thyroid Association.

GenMark Diagnostics said in a filing with the US Securities and Exchange Commission that Brian Mitchell, its senior vice president of operations, is no longer employed by the company.